Next Article in Journal
Deciphering the Mechanism of Action Involved in Enhanced Suicide Gene Colon Cancer Cell Killer Effect Mediated by Gef and Apoptin
Next Article in Special Issue
Multiplexed Immunohistochemistry for Molecular and Immune Profiling in Lung Cancer—Just About Ready for Prime-Time?
Previous Article in Journal
Loss of Stromal Galectin-1 Enhances Multiple Myeloma Development: Emphasis on a Role in Osteoclasts
Previous Article in Special Issue
The OncoAge Consortium: Linking Aging and Oncology from Bench to Bedside and Back Again
Article Menu
Issue 2 (February) cover image

Export Article

Open AccessReview
Cancers 2019, 11(2), 262; https://doi.org/10.3390/cancers11020262

Circulating Tumor Cell Detection in Lung Cancer: But to What End?

1,2,3,†, 1,2,†, 2,4, 1,2,3 and 1,2,3,*
1
Laboratory of Clinical and Experimental Pathology, CHU Nice, FHU OncoAge, University Côte d’Azur, 06100 Nice, France
2
Team 4, IRCAN, FHU OncoAge, University Côte d’Azur, CNRS, INSERM, 06107 Nice CEDEX 02, France
3
Hospital-Integrated Biobank (BB-0033-00025), CHU Nice, FHU OncoAge, University Côte d’Azur, 06100 Nice, France
4
Department of Pneumology and Oncology, CHU Nice, FHU OncoAge, University Côte d’Azur, 06100 Nice, France
*
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
Received: 22 January 2019 / Revised: 15 February 2019 / Accepted: 18 February 2019 / Published: 23 February 2019
  |  
PDF [602 KB, uploaded 23 February 2019]
  |  

Abstract

The understanding of the natural history and biology of lung cancer has been enhanced by studies into circulating tumor cells (CTCs). Fundamental and translational research, as well as clinical trials in the characterization and behavior of these cells, have constantly contributed to improving understanding within the domain of thoracic oncology. However, the use of these CTCs as prognostic and predictive biomarkers has not been adopted to the same extent as circulating free DNA (cf-DNA) in plasma, in the daily practice of thoracic oncologists. However, recent technological advances have firmly put the detection and characterization of CTCs in thoracic oncology back on the agenda, and have opened up perspectives for their routine clinical use. This review discusses the major advances of using CTCs in the domain of thoracic oncology, as well as the envisaged short- and long-term prospects. View Full-Text
Keywords: circulating tumor cells; liquid biopsy; lung cancer; personal medicine; techniques; xenograft circulating tumor cells; liquid biopsy; lung cancer; personal medicine; techniques; xenograft
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Hofman, V.; Heeke, S.; Marquette, C.-H.; Ilié, M.; Hofman, P. Circulating Tumor Cell Detection in Lung Cancer: But to What End? Cancers 2019, 11, 262.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top